Cargando…
Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
Triple-negative breast cancer (TNBC), a subtype distinguished by negative immunohistochemical assays for expression of the estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2(HER2) represents 15% of all breast cancers. Patients with TNBC generally experience a mo...
Autores principales: | Gucalp, Ayca, Traina, Tiffany A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265248/ https://www.ncbi.nlm.nih.gov/pubmed/22312556 http://dx.doi.org/10.1155/2011/696208 |
Ejemplares similares
-
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
por: Cadoo, Karen A, et al.
Publicado: (2014) -
Management Options in Triple-Negative Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2011) -
Treatment options for patients with triple-negative breast cancer
por: Santana-Davila, Rafael, et al.
Publicado: (2010) -
The advance of adjuvant treatment for triple-negative breast cancer
por: Ge, Jingyu, et al.
Publicado: (2022) -
Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)